Clomiphene citrate[ (Clomid) ] Drug Information

Contains Clomiphene citrate drug information and provides Clomiphene citrate drug indication, contraindication, special concerns, side effects, overdose management and dosage
Search Drugs by Generic or Trade Name:
Browse Drugs by Generic Name:
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z ]

To treat ovulatory failure in women desiring pregnancy and whose partners are fertile and potent. Normal liver function and normal levels of endogenous estrogen are necessary criteria to clomiphene use. Therapy is ineffective in clients with ovarian or pituitary failure. Investigational: Male infertility (controversial).
Back to Top
Pregnancy, liver disease or history thereof, abnormal bleeding of undetermined origin. Ovarian cysts or enlargement not due to polycystic ovarian syndrome. Uncontrolled thyroid or adrenal dysfunction, organic intracranial lesion (e.g., pituitary tumor). The absence of neoplastic disease should be established before treatment is initiated.
Back to Top
Special Concerns:
Multiple births are possible.
Back to Top
Side Effects:
Ovarian: Ovarian overstimulation and/or enlargement and subsequent symptoms resembling those of PMS. Ophthalmologic: Blurred vision, spots, or flashes, probably due to intensification of after images. Although cause and effect have not been established, the following have been noted in users of clomiphene: posterior capsular cataract, detachment of the posterior vitreous, spasm of retinal arteriole, and thrombosis of temporal arteries of retina. GI: Abdominal distention, pain, bloating, or soreness; N&V. GU: Abnormal uterine bleeding, breast tenderness, increased urination. CNS: Insomnia, nervousness, headache, depression, fatigue, lightheadedness, dizziness. Other: Hot flashes, allergic dermatitis, urticaria, weight gain, alopecia (reversible).
Back to Top
Overdose Management:
No Available information
Back to Top
Drug Interactions:
No Available information
Back to Top
•Tablets First course.

50 mg/day for 5 days. Therapy may be initiated at any time in clients who have had no recent uterine bleeding.

Second course.

Same dosage if ovulation has occurred. In absence of ovulation, dose may be increased to 100 mg/day for 5 days. This course may be started as early as 30 days after the previous one.

Third course.

Most clients who are going to respond will do so during the first course of therapy. Three courses are an adequate therapeutic trial. If ovulatory menses has not occurred, reevaluate diagnosis.
Back to Top